Does Kaiser Permanente Cover Mounjaro?
The verdict
Conditional on most plans
Kaiser Permanente covers Mounjaro for type 2 diabetes with prior authorization and a required semaglutide-first step — NorCal at Tier 3, SoCal at Tier 4. Mounjaro is not on Kaiser's 2025 Medicare Part D formulary (which lists Ozempic for diabetes instead). Medi-Cal (Kaiser's California Medicaid) excludes weight-loss GLP-1s effective 1/1/2026. Mounjaro is not covered for weight loss; the weight-loss tirzepatide is Zepbound.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Kaiser Permanente using your member ID.
Key facts
Kaiser Permanente requires semaglutide (Ozempic) step therapy before approving Mounjaro for type 2 diabetes — a Kaiser-specific formulary rule not common at other major insurers.
Kaiser Permanente regional drug formulary (NorCal/SoCal)
Medi-Cal (California Medicaid) excluded weight-loss GLP-1 receptor agonists effective January 1, 2026 — meaning Zepbound and Wegovy are no longer covered for obesity under Medi-Cal.
California Department of Health Care Services, Medi-Cal PDL update, 2026
Mounjaro (tirzepatide) is FDA-approved for glycemic control in adults with type 2 diabetes only. The weight-loss tirzepatide product — Zepbound — carries a separate FDA approval for chronic weight management.
FDA, Mounjaro and Zepbound Prescribing Information, 2023–2024
Medicare vs. commercial coverage
Whether Kaiser Permanente covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Mounjaro (tirzepatide) is NOT on Kaiser Permanente's 2025 Medicare Part D formulary. Kaiser's Medicare drug plan covers Ozempic (semaglutide) for type 2 diabetes instead. If you are on a Kaiser Medicare plan, verify the current-year formulary before assuming Mounjaro is covered — it may require a non-formulary exception request. Mounjaro is not in the 2026 Medicare GLP-1 Bridge, which covers weight-loss-approved products only. The Lilly savings card is not usable by Medicare beneficiaries. The IRA-negotiated MFN price of $245/month for Medicare begins mid-2026.
Commercial / Employer
Group & marketplace plans
Kaiser Permanente Commercial/Employer plans cover Mounjaro for type 2 diabetes with prior authorization and step therapy. NorCal region: Tier 3. SoCal region: Tier 4. Both require semaglutide-first step (patient must trial or fail Ozempic before Mounjaro is approved). Off-label weight-loss use is not covered. ACA/Individual: covered for T2D with PA and step therapy; weight-loss GLP-1s are restricted or excluded. Medi-Cal (California Medicaid): diabetes only — Medi-Cal excluded weight-loss GLP-1s effective 1/1/2026. The Lilly savings card ($25/month with coverage; $499/month without) is available to commercial patients only, not Medicare or Medi-Cal beneficiaries.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month; up to 13 fills; expires 12/31/2026). Not available to Kaiser Medicare or Medi-Cal enrollees.
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial: Kaiser cost-share by tier — NorCal Tier 3 / SoCal Tier 4 (verify specific copay on Kaiser drug list). Lilly savings card as low as $25/month for commercial members with coverage. Medi-Cal: nominal. Medicare (if approved by exception): 25% coinsurance to $2,100 OOP cap 2026; MFN $245/month mid-2026.
Typical monthly copay once prior authorization is approved.
All figures are estimates; actual cost-share varies by Kaiser region, plan tier, and pharmacy. Confirm on your Kaiser drug list or member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Check the Kaiser drug list for your region
Visit kp.org and navigate to your regional drug formulary (NorCal or SoCal). Search for 'Mounjaro' or 'tirzepatide' and note the tier (Tier 3 NorCal / Tier 4 SoCal), prior authorization requirement, and the semaglutide step-therapy condition. If you are a Kaiser Medicare member, verify the current-year Part D formulary — Mounjaro was not on the 2025 Kaiser Medicare formulary.
- 2
Work with your Kaiser prescriber on the PA and step-therapy documentation
Your Kaiser prescriber must document your confirmed T2D diagnosis, A1c, and prior trial of semaglutide (Ozempic). Kaiser's closed-network model means the PA is coordinated internally. If you have not yet tried semaglutide, your prescriber will typically start you on Ozempic before Mounjaro can be approved.
- 3
Call Kaiser member services to confirm coverage and formulary year
Call the number on your Kaiser card. Ask: Is Mounjaro on my plan's current formulary for type 2 diabetes? What tier and copay apply? Does step therapy with semaglutide apply? Is Mounjaro covered for weight loss? (Answer: No — diabetes-only. Weight-loss tirzepatide is Zepbound, covered separately.)
Options if Kaiser Permanente won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. Kaiser's formulary-preferred GLP-1 for diabetes and the required first step before Mounjaro can be approved. Covered on Kaiser's Medicare Part D formulary for diabetes.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative available on Kaiser formularies with prior authorization.
Jardiance (empagliflozin)
SGLT2 inhibitor approved for T2D with cardiovascular benefits. Commonly covered on Kaiser commercial and Medi-Cal plans.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and obstructive sleep apnea — not diabetes. Medi-Cal excludes weight-loss GLP-1s effective 1/1/2026. Coverage requires a separate weight-loss indication and is restricted under most Kaiser lines.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Mounjaro was not on Kaiser Permanente's 2025 Medicare Part D formulary. Kaiser's Medicare drug plan covers Ozempic (semaglutide) for type 2 diabetes instead. If you are on a Kaiser Medicare plan, verify the current-year formulary — you may need to request a non-formulary exception. Mounjaro is also not included in the 2026 Medicare GLP-1 Bridge, which covers weight-loss-approved products only.
No. Kaiser Permanente does not cover Mounjaro for weight loss under any line of business. Mounjaro is FDA-approved for type 2 diabetes only. Medi-Cal (California Medicaid via Kaiser) excluded weight-loss GLP-1s effective 1/1/2026. The weight-loss tirzepatide product is Zepbound, which has separate and more restricted coverage under Kaiser.
Kaiser Permanente's internal formulary requires step therapy — patients must trial semaglutide (Ozempic) for type 2 diabetes before Mounjaro can be approved. This is a Kaiser-specific formulary management decision. If Ozempic does not achieve adequate glycemic control or causes intolerable side effects, your Kaiser prescriber can document the failure or intolerance and submit for Mounjaro approval.
Mounjaro is Tier 3 on Kaiser NorCal commercial formularies and Tier 4 on Kaiser SoCal commercial formularies, based on publicly available Kaiser drug list information. Tier determines your copay or coinsurance. Verify the current tier and cost-share on your regional Kaiser drug list, as formulary placement can change annually.
Only if you have a Kaiser commercial (employer-sponsored or individual) plan, not Medicare or Medi-Cal. Commercially insured Kaiser members with Mounjaro coverage may pay as little as $25/month; without coverage, $499/month (max $647/month; up to 13 fills; expires 12/31/2026). The card is not available to Kaiser Medicare, Medicare Advantage, or Medi-Cal beneficiaries.
Related Articles
Does Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Mounjaro? 2026 Guide | Curex
BCBS covers Mounjaro for type 2 diabetes with prior authorization — not for weight loss. The weight-loss tirzepatide is Zepbound, with separate coverage.
Read moreDoes Blue Cross Blue Shield of Arizona Cover Mounjaro? | Curex
BCBS of Arizona covers Mounjaro for type 2 diabetes with prior auth — not weight loss. AZ Medicaid covers Wegovy for weight loss, but not Mounjaro.
Read moreDoes Blue Cross Blue Shield of Texas Cover Mounjaro? 2026 | Curex
BCBS of Texas covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The weight-loss tirzepatide is Zepbound, covered separately.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Mounjaro? HCSC 2026 | Curex
BCBS of Illinois (HCSC) covers Mounjaro for type 2 diabetes with PA — not weight loss. IL Medicaid covers T2D but excludes weight-loss GLP-1s.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
Kaiser covers Mounjaro for diabetes only, behind a semaglutide-first step, and excludes weight-loss GLP-1s on Medi-Cal from 1/1/2026. For patients seeking tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Kaiser Permanente before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.